It seems that investigating the effect of spironolactone on the sleep quality of patients with bipolar disorder, considering the mechanism of effect as an MR antagonist and its usefulness in the early stages of treating patients with bipolar disorder in manic episodes in our study, requires further evaluation in future studies using larger sample sizes and a longer duration of the clinical trial. Here, NR3C2 is linked to bipolar disorder.